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ABSTRACT 28 
The aim of this systematic review is to investigate the national diagnostic reference level 29 
(NDRL) methods for positron emission tomography/computed tomography (PET/CT) and 30 
single photon emission tomography/computed tomography (SPECT/CT) procedures. A search 31 
strategy was based on the preferred, reporting items for systematic review and meta-analysis 32 
(PRISMA). Relevant articles retrieved from Medline, Scopus, Web of Science, Embase,  33 
Cinahl, and Google Scholar published up to October 2017. The search yielded 1057 articles. 34 
Fourteen articles were included in the review after a screening process. Relevant information 35 
from the selected articles were summarised and analysed. Discrepancies were found between 36 
the methodologies utilised to establish and report both PET/CT and SPECT/CT NDRLs, e.g. 37 
patient sampling and administered activity. Further research should focus on reporting more 38 
NDRLs for hybrid PET/CT and SPECT/CT examinations, and establish a robust NDRL 39 
standard for the CT portion associated with PET/CT and SPECT/CT examinations. This review 40 
provides updated NDRL reommndations to deliver more comparable international radation 41 
doses for administered activity and CT dose across PET/CT and SPECT/CT clinics. 42 
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 49 
Introduction 50 
Hybrid modalities integrating positron emission tomography (PET) or single photon emission 51 
computed tomography (SPECT) with X-ray computed tomography (CT) enable intrinsic co-52 
registration of functional and anatomical data in a single procedure (PET/CT or SPECT/CT)(1-53 
3). The introduction of hybrid medical imaging technology has revolutionised the practice of 54 
diagnostic nuclear medicine (NM). PET/CT and SPECT/CT have wide acceptance for many 55 
clinical investigations such as oncology, neurology, cardiology and psychiatry(4). The CT 56 
aspect is often a low-dose CT scan to provide attenuation correction (CT-AC), anatomical 57 
localisation (CT-AL), or diagnostic CT procedures with or without contrast media(4-6). The 58 
fused information from PET or SPECT with CT data can result in superior diagnostic accuracy 59 
for localisation, detection, staging and monitoring of many disease mechanisms compared to 60 
PET, SPECT or CT alone(7). 61 
A concern with PET/CT and SPECT/CT imaging is the combined radiation doses from both 62 
radiopharmaceutical and X-ray CT components(8, 9). The lifetime attributable risk of cancer 63 
incidence for fluoride-18 fluorodeoxyglucose (18F-FDG) whole-body PET/CT scans for 20-64 
year-old males and females in the United States of America (USA) has been reported to be up 65 
to 0.323% and 0.514% respectively(10). Therefore, it is imperative to implement a radiation 66 
dose optimisation process by utilising the “as low as reasonably achievable” (ALARA) 67 
principle to protect patients from unwarranted high radiation burdens and to minimise the 68 
probability of inducing cancer. However, McCullough(11) reported there is no reliable evidence 69 
to demonstrate risks of medical imaging at low doses (<50 mSv), which includes the majority 70 
of NM examinations. 71 
The International Commission on Radiological Protection (ICRP) publication 60 introduced 72 
diagnostic reference levels (DRLs) in 1990, and its implementation was recommended in the 73 
ICRP 73 1996 publication(12). In 1997, the European medical exposure directive defined DRLs 74 
as “dose levels in medical radio-diagnostic practice or, in the case of radiopharmaceuticals, 75 
levels of activity, for typical examinations for groups of standard-sized patients or standard 76 
phantoms, for broadly defined types of equipment. These levels are not expected to be 77 
exceeded for standard procedures when good and normal practice regarding diagnostic and 78 
technical performance is applied”(13). DRLs are advisory in nature and not dose limits. Their 79 
role is to draw attention to the issue of radiation protection and safety and thereby reduce the 80 
radiation doses to patients. However, one needs to acknowledge that the radiation dose can 81 
acceptably exceed the national DRL (NDRL) value in some circumstances due to the patient's 82 
characteristics or disease factors that require deviation from standard procedures. The DRLs 83 
should be refined over time based on improvements in standard procedures and equipment(14). 84 
Implementing DRLs enables identification of variations between high and low dose imaging 85 
protocols and equipment(14). This is possible through comparing mean or median local DRL 86 
against national or regional DRL for equivalent representative groups of patients undergoing a 87 
specific typical procedure. Where the value of the mean or median local DRL dose exceeds the 88 
accepted NDRL value without convincing medical justification, this triggers the need for 89 
equipment performance or imaging protocol review for dose optimisation(3).  90 
The DRLs in PET/CT and SPECT/CT are determined by collecting radiation doses from the 91 
administered activity (A) measured in megabecquerel (MBq) as well the CT dose in volume 92 
CT dose index (CTDIvol) measured in milligray (mGy) and the dose length product (DLP) 93 
measured in milligray times centimetre (mGy.cm)(15). Two different measures are used to 94 
report DRL values for the A, namely the 75th percentile and guidance level. The 75th percentile 95 
method is based on the evaluation of the distribution of median A from participant centres in a 96 
national or regional DRL survey. It is used to report the DRLs for both A and CT dose(16, 17). 97 
Evidence gathered by expert professional organisations is used to establish guidance levels on 98 
a national level for a standard-sized patient(16). Guidance levels are used to report recommended 99 
A but not CT dose. 100 
The achievable dose provides an additional reference level for optimising diagnostic imaging 101 
without compromising image quality(18, 19). The achievable dose corresponds to the 50th 102 
percentile of the NDRL and is used to identify the dose commonly used in clinical practice. 103 
Centres with a local DRL just below the 75th should focus on optimising the acquisition 104 
protocol and equipment with an aim to approach the achievable dose(18, 19).  105 
The administered activity duration product (ADP) has been proposed as an additional unit for 106 
NM DRLs(19). The ADP is a product of the A and acquisition time (MBq.min). The ADP is 107 
considered a better measure for dose optimisation, compared to A (MBq) alone, as A and 108 
imaging time both impact on image quality(19). The photon density in a NM image is directly 109 
proportional to the ADP. Therefore, administering the same recommended activity to patients 110 
in different centres may not yield the same image quality as some facilities will use different 111 
total acquisition times due to variations in imaging equipment sensitivity(19). Thus, reporting 112 
both MBq and MBq.min units for DRL and ADP reference levels provides additional 113 
information about photon flux which impacts on image quality. 114 
The establishment of DRLs for PET/CT and SPECT/CT imaging is an essential step in 115 
recognising variations between radiation doses delivered to the patient using a diverse range of 116 
equipment and changing protocols(14). The existing PET/CT and SPECT/CT, PET, SPECT, and 117 
CT component methods are prone to some limitations due to diverse methods implemented for 118 
population selection, different reporting methods, the impact of new imaging technology, and 119 
reporting effective dose (E) from both the A and CT(15, 18-30). The purpose of this systematic 120 
review is to determine the variations in reported NDRL methodology and values for adult 121 
PET/CT and SPECT/CT procedures.  122 
Material and Methods 123 
Search strategy 124 
A research protocol for the review was selected and designed before undertaking our database-125 
driven research. This included writing a clear protocol to address the research question, 126 
followed by creating keywords that would help us search data across a diversity of databases. 127 
No industry funding was obtained for this systematic review, which was conducted in line with 128 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 129 
guidelines. The preferred reporting items for PRISMA methodology was used to search for 130 
articles published up to October 2017(31). A systematic literature search of Medline, Scopus, 131 
Web of Science, Embase, and Cinahl was performed to identify the essential articles that 132 
established hybrid DRL NM procedures for adult patients. To access more information, 133 
reference lists of published articles were examined to identify additional articles not identified 134 
in the database searches. Literature Boolean search was performed using the following method 135 
and terms: Intervention (“Diagnostic reference levels” or “Diagnostic reference activities” or 136 
“DRLs”) AND cohort (“Positron emission tomography/computed tomography” or “Single 137 
photon emission computed tomography/ computed tomography” or “Positron emission 138 
tomography” or “Single photon emission tomography” or “Computed tomography” or 139 
“Nuclear medicine” or “PET/CT” or “SPECT/CT” or “PET” or “SPECT” or “CT” or “NM”) 140 
OR other (“PET radiopharmaceutical” or “Radiopharmaceutical”). The search was limited to 141 
include all the articles that had been published in the English language. 142 
Criteria for selection 143 
All cohort studies were selected based on the inclusion and exclusion criteria developed, 144 
through the use of a population, intervention, comparison, and outcomes (PICO) methodology 145 
Table 1. Articles were considered for the review if they described NDRLs of adult patients 146 
undergoing PET/CT and SPECT/CT procedures. Articles that did not fulfil these criteria were 147 
excluded as were case studies, posters, narrative literature reviews, and case reports. All articles 148 
included contained the theme of measurement methods for adult NDRLs with PET/CT and 149 
SPECT/CT examinations (Table 1). The funding sources for each selected study were assessed 150 
as part of the review. 151 
Quality assessment  152 
The quality assessment was performed by two reviewers (EA and PK). These reviewers 153 
developed an Excel data extraction sheet based on the quality assessment tool for quantitative 154 
studies, as developed by the Effective Public Health Practice Project (EPHPP)(32). An Excel 155 
datasheet was used to assess a study’s design, to determine whether it satisfied the data 156 
selection criteria. The developed Excel data extraction sheet was used independently by each 157 
reviewer to evaluate the risk of bias and to pinpoint any poor-quality or irrelevant publications. 158 
Data extractionTwo reviewers (EK and PK) independently evaluated articles for quality and 159 
for risk of bias, to ensure that they satisfied the inclusion criteria. Data extraction was 160 
undertaken, based on the following characteristics in each study: hybrid type, equipment, 161 
population, reporting for PET or SPECT, reporting method for CTDIvol, reporting method for 162 
DLP, and E. The reviewers were aware of large variations among the included studies, in terms 163 
of their NDRL methods. Each article was reviewed based on the PICO approach; the extracted 164 
data were compared between two reviewers, and wherever there was disagreement, all 165 
variations in opinion were subsequently resolved through discussion. An identified article was 166 
independently scored as high (1), moderate (2), or low (3) by each reviewer. As recommended 167 
by the reviewer, only articles rated as high (1) or moderate (2) by reviewer were included in 168 
this review. 169 
 170 
Results 171 
The combined search strategy identified 1057 articles: 169 from MEDLINE (OVID), 278 from 172 
Web of Science, 326 from Embase, 265 from Scopus, 17 from CINAHL, and two from Google 173 
Scholar. Of these, 413 articles were duplicates and deleted, leaving a total number of 644 174 
articles. The 644 articles were assessed for the eligibility, of these, 611were excluded on initial 175 
screening of titles and abstracts. Thirty-three articles met the criteria for a full-text review and 176 
were evaluated utilising the inclusion and exclusion criteria of PICO methodology. Nineteen 177 
articles were excluded due to insufficient data for evaluation of methods, reporting local DRL, 178 
conference, oral presentation, and case report. As a result, fourteen articles met the selection 179 
criteria as shown in Figure 1. All studies were rated highl and moderate  and were used to 180 
assess variations in the determined NDRL method and values among adult patients undergoing 181 
PET/CT and SPECT/CT procedures. Two NDRL articles reported funding support for their 182 
surveys, but the other did not. These two articles were funded by the Japanese Society of 183 
Nuclear Medicine(21)”, while the other article was funded by The English Department of 184 
Health(29). 185 
A summary of the fourteen articles is illustrated in Tables 2 and 3. Two countries have 186 
established the NDRL for PET/CT and one for SPECT/CT examinations. Most NDRL 187 
publications were related to either PET or SPECT component and two for CT component only. 188 
Seven NDRL articles were from Europe(18, 20, 24, 25, 27, 29, 30), two from the United States of 189 
America(19, 23), two from Brazil(22, 26), and single articles from Australia and New Zealand(28), 190 
Korea(15) and Japan(21). The articles were published between 2002 to 2017, with the majority 191 
published between 2013 to 2017. 192 
The methodology for determining patient selection varied. Two common methods for selecting 193 
the patient sample reported in the literature were weight and non-weight restriction. The weight 194 
restriction method involves selecting at least 20 patients whose weights are 70 ± 10 or 75 ± 25 195 
kg(25, 27, 28). Three articles reported NDRL values based on weight criteria for PET/CT and PET 196 
examinations.  The non-weight restriction method involved selecting a range of 1 to 76 patients 197 
for each PET/CT, SPECT/CT, PET, SPECT, and CT component associated with PET and 198 
SPECT  examinations. Six articles adopted non-weight restriction approach(15, 18-20, 23, 24) and 199 
five articles did not provide any details of the patient sampling(21, 22, 26, 29, 30).  200 
The most frequent imaging procedures were 18F-FDG PET and 99mTc- methyl diphosphonate 201 
(MDP) SPECT bone scans with a range of reported NDRLs for an A of 200 to 592 MBq and 202 
600 to 999 MBq, respectively (Table 2 and 3). Some of the identified articles reported clinical 203 
indications for PET/CT and SPECT/CT examinations. A total of six articles identified tumours 204 
for PET/CT examinations. Of the six articles, two reported the 18F-FDG value used for both 205 
tumour and infection/inflammation clinical indication. Only one article reported the common 206 
clinical indications for six SPECT/CT examinations and the other article reported the clinical 207 
indication for SPECT/CT thyroid metastasis(18, 24).   208 
There were five manufacturers of PET/CT and SPECT/CT equipment using six different NM 209 
detectors installed between 2000 and 2015 reported (Table 4). Two articles reported both the 210 
manufacturer and model of PET/CT equipment(15, 24). One article reported the number CT rows 211 
only, e.g. 2 and 16 slice(24). One article reported CT-AC and AL acquisition parameters 212 
associated with a 18F-FDG whole-body scan, while another article reported scan length for six 213 
PET/CT and SPECT/CT examinations(18, 23).  214 
A NDRL for the CT component used for AC and AL and AC only was reported in three and 215 
one article, respectively(15, 18, 23, 24, 27). No authors reported the NDRL for the CT component 216 
when used for diagnostic CT. All 18F-FDG PET/CT whole body CTDIvol values were lower 217 
than the NDRL of 15 mGy, as reported by the Australian Radiation Protection and Nuclear 218 
Safety Agency (ARPANSA) for diagnostic chest CT(33). 219 
Different approaches were used to report NDRL in the review. Twelves articles reported NDRL 220 
values based on the 75th percentile(15, 18-23, 26-30), and two articles based on guidance level(24, 25). 221 
In addition to the NDRL, two articles also reported achievable dose and one article reported 222 
ADP(18, 19). There were seven articles reported their recommended A  strategy, e.g. MBq/kg(15, 223 
19-21, 25-27). Two articles reported NDRLs for 18F-FDG based on TOF technology(20, 27). 224 
Seven articles reported the E, three articles for both A and CT(15, 24, 27), three articles for A 225 
only(22, 29, 30) and one article for the CT only as seen in Tables 2 and 3.  226 
Discussion 227 
The patient selection methods used to determine the NDRL for PET/CT, SPECT/CT, PET, 228 
SPECT and CT for hybrid imaging procedures were varied, see Table 2 and 3. The weight 229 
restriction and non-weight restriction are two commonly accepted methods for selecting 230 
patient’s sample for DRL survey. The weight restriction method involves selecting at least 20 231 
to 30 standard size patients, with the mean weight of patients in the sample being 70 ± 5 kg(3). 232 
For the current European NDRL project, another patient weight criteria was 70 ± 15 kg; the 233 
number of samples collected using the survey was not mentioned(34).  Several NDRL articles 234 
have indicated the patient weight and these are presented under the patient characteristics of 235 
patient samples in Tables 2 and 3. Watanabe et al. argue that it is necessary to conduct NDRL 236 
articles based on weight restriction criteria because of variations in patient habitus and weight 237 
may have an impact on the results(21). The weight restriction method allows data comparison 238 
with other published NDRL using the same approach for PET/CT and SPECT/CT imaging. 239 
For the non-weight restriction method, some NDRL methods for NM, PET/CT and SPECT/CT 240 
examinations were used to collect all present patients during a time frame acceptable for the 241 
NDRL survey(3). The non-weight restriction method has some advantages compared to weight 242 
restriction method. Applying the weight limit criteria for the population sample may reduce the 243 
availability of data and extend the data collection period(16, 35). Using the NDRL method 244 
without weight restriction may result in a larger patient sample, which should lead to improved 245 
understanding of patient weights in a national population (35).  246 
The literature showed the numbers of patients sampled using weight and non-weight restriction 247 
methods ranged from 1–76 patients. For the weight restriction method, the patient samples 248 
ranged from 20–30 patients with different weight-standard criteria(20, 25, 27). However, two 249 
articles reported NDRLs based on sample sizes that were too small (for example, lower than 250 
ten patients)(19, 24). For the non-weight restriction method, the samples varied and were 251 
collected over different time frames, which ranged from four months to one year. Iball et al. 252 
demonstrated UK's NDRL method aimed to collect 30 patients over five months for PET/CT 253 
and SPECT/CT examinations(18). Iball et al. concluded that patient weight data only existed for 254 
a small number of PET/CT and SPECT/CT examinations; therefore, the UK's NDRL method 255 
was limited to reports of NDRLs based on a standard patient size of 70 ± 10 kg(18). The average 256 
number of patients in the non-weight restricted NDRL articles was 38. The current ICRP 135 257 
recommends when collecting 50 or more patients during NDRL survey, weight restriction is 258 
not required(3). However, some authors found similar NDRL results, less than 2% difference, 259 
when using either weight or non-weight restriction method(36, 37). Future PET/CT and 260 
SPECT/CT NDRL methods should involve a minimum of 50 patients with a non-weight-261 
restriction approach(3). A NDRL method based on the selection of a large number of patient 262 
sample enables filtering the data by different patient body sizes better enabling NDRL data 263 
comparison(38, 39), e.g. retrospectively selecting 30 patients with weight restriction (70±15 kg) 264 
acquired from a non-weight-restriction data(18, 20, 40). 265 
Some articles reported PET/CT, PET and SPECT/CT NDRLs for clinical indications. Iball et 266 
al. provide 18F-FDG PET/CT NDRL, CTDIvol and DLP, for two clinical indications for half 267 
body imaging and 99mTc-phosphates SPECT/CT NDRL, CTDIvol and DLP, for six common 268 
clinical indications for bone imaging(18). Willegaignon et al. demonstrated that the amount of 269 
18F-FDG A for the most PET/CT common indications related to oncological and 270 
infection/inflammation was 350 MBq(22). The European Association of Nuclear Medicine 271 
(EANM) guidelines illustrate that administered activity of 99mTc-MDP is 370-740 MBq for the 272 
most common clinical indications for three phase or whole body SPECT/CT bone scans(41). 273 
The literature reveals that the recommended NDRL for A will be the same for common patient 274 
clinical indications in relation to PET/CT and SPECT/CT procedures. The amount of A differs 275 
when different radiopharmaceuticals are used for different PET/CT and SPECT/CT procedures 276 
(Table 2 and 3).  277 
Body region was another area that varied across studies. Several publications have asserted that 278 
variations in CT scan range or body region associated with oncological PET/CT protocols and 279 
SPECT/CT bone protocols depend on patient clinical indication demonstrating a lack of 280 
standardisation(42-45). For 18F-FDG PET/CT procedures the most common CT range was varied 281 
from the mid-femora to the external auditory meatus, and from the top of the head to the feet 282 
for tumours that show a high probability of metastasis in the brain, skull or lower extremities, 283 
e.g. melanoma. A more limited CT range for tumour imaging may be considered when a patient 284 
returns for follow-up imaging(6, 46). The literature reveals that the reported NDRL DLP values 285 
for 18F-FDG whole body PET/CT scans varied from 400 to 750 mGy.cm due to various scan 286 
range descriptions, with only one NDRL article providing the scan range for the most common 287 
clinical indications related to 18F-FDG whole body scans(15, 18, 27). ARPANSA reported that the 288 
NDRL for PET/CT and SPECT/CT examinations takes into account the scan region and the 289 
CT used for the AC or AL to cover a wide range of clinical indication for each examination(33). 290 
The first and second scan ranges for the whole body CT protocol are started from the eyes to 291 
the thighs and from the vertex to the toes, respectively. For SPECT/CT, Gardner et al. provides 292 
local DRL values for bone and neuro-endocrine SPECT/CT procedures takes into account 293 
different anatomical body regions and the purpose of CT used for each anatomical regions(45). 294 
Four different anatomical body regions were identified for neuro-endocrine SPECT/CT 295 
procedures known as abdomen, abdomen/pelvis, chest/abdomen/ pelvis, and 296 
head/chest/abdomen/pelvis and the DLP values for each anatomical body region were 280, 297 
204, 204, and 377, and 373 mGy.cm respectively(45). Furthermore, the scan length might be 298 
increased if the NM physician found a new metastatic lesion requiring additional CT 299 
investigation(18). However, scan length is a crucial parameter influencing a patient’s CT dose 300 
and is directly associated with DLP(18). A longer scan length involves a greater number of slices 301 
over a larger anatomical region, which subjects the patient to higher radiation exposure. Iball 302 
et al.  suggested that limiting the scan length to only the area requiring investigation would 303 
optimise radiation doses delivered from PET/CT and SPECT/CT examination used in British 304 
clinical centres(18). Thus, an NDRL method for PET/CT and SPECT/CT should provide a clear 305 
description of the clinical indications in relation to PET/CT and SPECT/CT examinations, the 306 
administered radiopharmaceutical, and the scan range of anatomical regions(18, 33, 45). 307 
Improvements to PET/CT and SPECT/CT hardware and software allow a reduction in radiation 308 
exposure to patients or shorter scanning times while maintaining acceptable image quality(47). 309 
Recent improvements to PET and SPECT include additional scanner rings for PET, 310 
scintillation detector materials including cadmium-zinc-telluride (CZT) detectors with novel 311 
collimators for SPECT, and reconstruction algorithms which incorporate time of flight (TOF) 312 
and point spread function (PSF) modelling(40, 48). Kwon et al. demonstrate that using a PET/CT 313 
unit equipped with TOF technology and PSF algorithms required less administered activity(15). 314 
Two articles reported NDRL for 18F-FDG whole-body based on TOF technology. Roch et al. 315 
and Etard et al. reported that the A for 18F-FDG whole-body scans decreased from 360 to 260 316 
MBq and from 300 to 250 MBq with PET/CT systems equipped with TOF technology, 317 
respectively(20, 27). However, Roch et al. noted that insufficient numbers of centres with 318 
SPECT/CT units equipped with CZT participated in the survey, therefore, appropriate NDRL 319 
could not be provided for this new technology(20). Furthermore, innovations in CT components, 320 
including automatic tube current modulation, automatic tube voltage selection (ATVS), and 321 
iterative image reconstruction algorithms, enable minimisation of radiation dose without 322 
compromising image quality(49). Kwon et al illustrate that CT AC and AL radiation doses 323 
delivered from CTDIvol and DLP were significantly reduced with the use of a recently installed 324 
PET/CT instrument(15). Many authors assert that current technical innovations in PET/CT and 325 
SPECT/CT modality enable a reduction in radiation exposure to the patients and while 326 
maintaining image quality(47, 49). However, the literature reveals that no image quality criteria 327 
exist to assess PET and SPECT image quality; nor are there any criteria for CT to assess AC 328 
and/or AL image quality associated to PET and SPECT examinations. In diagnostic radiology, 329 
an expert group of radiologists and physicists published European guidelines on quality criteria 330 
for CT(50). The main objective of the European guidelines is to provide minimum CT radiation 331 
dose while ensuring the obtainment of acceptable image quality criteria. Thus, NM researcher 332 
should develop methods to explore the acceptable balance between scan time and should 333 
develop image quality criteria and patient radiation dose reductions for PET/CT and 334 
SPECT/CT imaging modalities.  It is recommended that when reporting NDRL the study takes 335 
into the account the manufacture date of equipment, and the current technological advances in 336 
PET/CT and SPECT/CT equipment, e.g. TOF and CZT scintillation detectors, respectively, as 337 
these technologies enable a reduction in the administered dose.  338 
Some authors recommended that the achievable dose and ADP be used as supplementary dose 339 
measures for PET/CT and SPECT/CT NDRLs for identifying radiation doses yield suitable 340 
diagnostic image quality(18, 19). Iball et al. found that CT doses vary significantly for the same 341 
procedures and the same clinical indication and conclude that radiation doses may be reduced 342 
by establishing both DRLs and achievable dose for British clinical practices(18). Alessio et al. 343 
argues that NDRL and achievable dose reference levels for PET and SPECT A are limited as 344 
they do not consider the impact of total acquired photons on image quality(19). Alessio et al. 345 
recommends including ADP, which incorporates acquisition time, with NDRL as a practical 346 
way to overcome this limitation(19). Determining ADP is a challenge for PET or SPECT 347 
examinations, due to variations in A and scan duration among clinical centres. Some clinical 348 
centres reduce A to patients and increase scan duration to maintain image quality. However, a 349 
drawback of increased scan duration is that some patients are unable to remain still for long 350 
durations, resulting in motion artefacts which degrade image quality(3). In some circumstances, 351 
scanning obese patients required an increase in the A to ensure the maintenance of diagnostic 352 
image quality. From a radiation protection point of view, increasing A to patients minimises 353 
scan duration and should not be performed on the basis of increased department workflow(3). 354 
However, only one article reports on ADP quantity, so the usefulness of the collection of the 355 
scan duration to assist in the determination of the ADP has not been fully explored. From the 356 
authors’ perspective, it is important to determine the ADP to identify the normal clinical 357 
practice and understand the trade-off between the A and the scan duration required to maintain 358 
diagnostic image quality. Alessio et al. reported the ADP values for 18F-FDG PET/CT and 359 
99mTc-MDP SPECT/CT scans to provide clear guidelines for clinical practice to ensure the 360 
obtainment of sufficient image quality(19). The authors illustrate that determining the ADP 361 
requires the collection of the administered activity and scan duration during the NDRL survey 362 
from participant clinical centre, which is easy to perform. The authors conclude that if the ADP 363 
value is consistently higher than the reported national ADP values, then the clinical practice 364 
should optimise the A, adjust the scanning time or both to ensure that sufficient image quality 365 
is obtained(19). Therefore, future PET/CT and SPECT/CT NDRL methods should report both 366 
75th percentile (DRL) and 50th percentile achievable dose to encourage clinical centres to 367 
optimise and improve their clinical practice. NDRL methods should collect data on A and 368 
acquisition time to evaluate the value of ADP, as a DRL metric.  369 
All but one of the presented PET/CT and SPECT/CT NDRL methods failed to report the details 370 
of CT acquisition protocols(23). Investigating radiation doses delivered from different CT 371 
acquisition protocols aids in dose optimisation(8). However, the details of the acquisition are 372 
important to investigate the differences between NDRLs and to assist with optimisation. The 373 
NDRL method should be easy to perform and serve as a guideline to ensure that the median 374 
radiation dose metric delivered from clinical centres is equal to or lower than the recommended 375 
75th percentile of the NDRL standard(3, 19). The reported NDRL values should be used as a way 376 
to underpin optimisation strategies. The optimisation process is separate to the DRL process 377 
and should be initiated at the level of clinical practice when the median radiation dose quantity 378 
of clinical centre exceeds the 75th percentile of NDRL standard without justifiable reason(3, 19). 379 
Optimising CT components associated with PET/CT and SPECT/CT procedures would be 380 
achieved by modifying CT acquisition parameters, such as by lowering kVp and mAs values, 381 
or selecting a larger pitch ratio without compromising diagnostic image quality(8). It is practical 382 
to report the NDRL standard and collect the CT parameters to understand the details of CT 383 
acquisition protocol and variation between all participant centres. Jallow et al. reported the 384 
NDRL for CTDIvol and collected all CT acquisition parameters associated with 
18F-FDG 385 
oncological imaging procedures in United States PET/CT clinical centres(23). They 386 
demonstrated that the 75th percentile of CTDIvol associated with 
18F-FDG PET/CT oncological 387 
procedures was 9.8 mGy. Their results highlighted a wide range of CT acquisition parameters 388 
among participants clinical centres such as tube current, pitch ratio and collimation, which 389 
ranged from 20–450 mA, 0.5–2, and from 5–40 mm, respectively(23). The diversity of CT 390 
acquisition parameters indicates there is an opportunity to optimise CT acquisition protocols 391 
for 18F-FDG whole-body PET/CT examinations. Thus, it is more practical to report PET/CT 392 
and SPECT/CT NDRL methods and report the details of the CT acquisition protocol to assist 393 
in the development of dose optimisation strategies(23).  394 
NDRL units for A are either A (MBq) or A per unit of body weight (MBq/kg). The 395 
recommended A depends on several factors such as equipment type, patient weight, acquisition 396 
protocol and reconstruction method(6, 51). It is important to illustrate that weight-based A is not 397 
appropriate for some SPECT/CT examinations, in which the A is concentrated in a single 398 
organ, such as thyroid and sentinel node examinations, as well as pulmonary ventilation and 399 
perfusion examination(3). The methods that NM clinics use to determine A to patients are 400 
varied, some use fixed methods or follow international guidelines, while others use weight-401 
based methods(26). Alessio et al. examined different strategies for A for 18F-FDG whole-body 402 
PET/CT and 99mTc-MDP SPECT bone examinations(19). They reported no statistical 403 
differences in the average A for fixed, range, and weight-based strategies. They also found that 404 
PET/CT (n=3) and SPECT/CT (n=1) mobile clinics delivered higher radiation doses than the 405 
non-mobile clinics by 30% and 40%, respectively, due to the utilisation of fixed methods for 406 
determining A(19). Oliveria et al. illustrate that adjusted 18F-FDG weight-based strategies 407 
greatly varied among two clinics using PET/CT equipment from the same manufacturer and 408 
with same scintillation detectors (3.7 MBq.kg-1 to 7.4 MBq.kg-1), illustrating a lack of 409 
standardisation and a potential to optimise the 18F-FDG dose(26). Roch et al. claimed that the A 410 
recommendations should be determined based on patient weight(25). Adopting weight-based 411 
strategy enables to explore the variations for the A between clinical centres. Thus, NDRL 412 
surveys should report the recommended administered strategy based on patient weight 413 
(MBq/kg) for all PET/CT and SPECT/CT examinations in order to provide suitable guidelines 414 
for clinical centres(25).  415 
The effective dose (E) was also reported for the majority of PET/CT, SPECT/CT, PET, SPECT 416 
and CT components associated with PET and SPECT procedures during NDRL surveys 417 
(Tables 2 and 3)(15, 18, 22, 24, 27, 29, 30). The E from PET/CT and SPECT/CT is defined as the sum 418 
total of the radiation dose (mSv) from the A and from the CT components allowing 419 
quantification of total radiation exposure (Total E (mSv) = ENM +ECT) and radiation risk
(52, 53). 420 
The E method in PET/CT and SPECT/CT is calculated by multiplying each radiation dose by 421 
specific conversion coefficients assigned for the A and the DLP value for the CT dose(52). Some 422 
researchers used the Monte Carlo software programme to calculate the E value for CT doses  423 
such as CT-Expo software version 2.1 and 2.4 (Medizinische Hochschule Hannover Germany) 424 
and ImPACT scan CTDI dosimetry software (version 1.0.4 with the National Radiological 425 
Protection Board (NRPB) SR250 dose data)(15, 23, 24, 27). However, E methods are based on 426 
assumptions about patients that are not commonly true due to variation in size and physiology. 427 
At the moment, the E methods described seem straightforward; however, the results of E values 428 
are prone to a lack of precision. Calculating E for the A requires multiplication by a conversion 429 
coefficient taken from the ICRP tables. The result of E from CT varies amongst different CT 430 
dosimetry software due to the various methods and algorithms utilised for each software 431 
program(54).  432 
Reporting E is the only way to merge the radiation doses into one metric from the total radiation 433 
doses delivered from PET/CT and SPECT/CT examinations. The reporting of E from PET/CT 434 
and SPECT/CT procedures enables us to understand the variation of radiation doses delivered 435 
from each radiation dose component and supports a dose optimisation strategy. However, the 436 
ICRP 135 publication illustrates that reporting the E should not be a part of NDRL methods(3). 437 
It is impractical to use E comparisons when a wide range of patients’ ages and genders are 438 
being compared because it is subjected to large uncertainty(40). Shrimpton et al explained that 439 
E data were excluded from the UK NDRL survey because E has a different purpose than 440 
NDRL(55). The exact method for calculating E is complex and requires collecting extra 441 
information about patients’ individual biokinetics, physiological and anatomical properties for 442 
A and a number of CT parameters such as beam energy and beam filtration(36). The E is subject 443 
to much uncertainty; therefore, it is not yet recommended to be a part of NDRL methods(3).  444 
Further research is required to investigate the role of E in developing dose optimisation 445 
strategies.  446 
Recommendations 447 
Based on this extensive review, we suggest the following recommendations: 448 
1. It is recommended that PET/CT and SPECT/CT NDRL methods adopt a non-weight 449 
restriction approach and then filter the data acquired for the purpose of international 450 
data comparison.  451 
2. A clear description of the administered radiopharmaceutical and scan range for CT 452 
components should be provided for each PET/CT and SPECT/CT examination.  453 
3. NDRL methods should assess the usefulness of achievable dose and ADP as a DRL 454 
metric for A.  455 
4. It is recommended that NDRLs report the DRLs for PET/CT and SPECT/CT 456 
procedures for equipment equipped with or without TOF and CZT technology. 457 
5.  Reporting the NDRL with details of CT acquisition parameters will underpin the dose 458 
optimisation strategy programme. 459 
6.  It is recommended that NDRLs of PET/CT and SPECT/CT report the A per patient 460 
weight for each exam.  461 
7. Finally, the E value should not be reported as NDRL metric as it is based on a number 462 
of assumptions impacting on its accuracy.   463 
Conclusion  464 
The literature shows differences in methods for establishing DRLs for PET/CT and SPECT/CT 465 
examinations. Findings also show variations in reported PET/CT and SPECT/CT DRLs arise 466 
from patient characteristics, methods reporting, and progress of the technology. NM 467 
professions should report both radiation doses from the A and the CT dose used for different 468 
purposes rather than report a separate NDRL for A or CT dose. Further research should be 469 
performed to assist in the international standardisation of data collection and reporting of 470 
NDRL PET/CT, with more attention given to SPECT/CT procedures. 471 
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Table 1. Criteria for determining study eligibility. 661 
Characteristics  Criteria 
Study year Articles published up to October 2017. 
Study type Cohort studies 
Population Adult patients undergoing PET/CT and SPECT/CT examination 
Intervention Adult DRL measurement methods for PET/CT and SPECT/CT examinations 
Comparator Reliability of DRL methods for adult in PET/CT and SPECT/CT examinations 
Reproducibility of DRL methods for adult in PET/CT and SPECT/CT 
examinations 
Outcomes PET/CT and SPECT/CT DRL methods for adult patients. 
 662 
Table 2. Summary of hybrid PET/CT DRL methods. 663 
Authors 
(Years & 
Country) 
Procedure Clinical 
indication 
Radiotracer Scan range Characteristic of 
patient sample 
DRL dosimetry value E (mSv) 
A(MBq) 
[MBq/kg] 
CTDIvol and DLP 
(mGy) & 
(mGy.cm) 
A CT Total 
Kwon et al15 
(KO, 2016) 
Whole body - 18F-FDG Base of skull- 
upper thigh 
10 per each exam 370 
[5.89±1.46] 
5.96 and 560 5.89 6.26 12 
Etard et al27 
(FR, 2012) 
Whole body 
 
- 18F-FDG At least  neck- 
thigh 
20 (50-100 kg) 350 
[4.3] 
250 
[3.5 TOF] 
8 and 750 5.7 8.6 14 
Iball et al18 
(UK,2017) 
Half body Tumour 
 
Infection/   
Inflammation 
18F-FDG Base of brain- 
mid thigh 
30 per each exam - 4.3 and 400 7.6 6.5 14 
Roch et al20 
(FR, 2017) 
Whole body 
 
- 18F-FDG - 30 per each exam 350 
 
260 
[3.6 TOF] 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
Watanabe et 
al21 
(JP, 2016) 
Tumour 
 
Tumour 
 
Tumour 
 
Brain 
 
Tumour 
 
Tumour 
 
Tumour 
 
- 
 
- 
 
- 
 
- 
 
- 
18F-FDG HP 
 
18F-FDG  
(Delivery) 
18F-FDG HP 
 
18F-FDG  
(Delivery) 
15O-CO2 g: 2D 
 
15O-O2 g: 2D 
 
15O-CO g: 2D 
 
15O-CO2 g: 3D 
 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 235 
[2-5] 
252 
[2-5] 
227 
 
255 
 
7500 
 
4500 
 
3000 
 
2888 
 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
 
 
Table 2. Summary of hybrid PET/CT DRL methods (continued). 664 
  665 
Authors 
(Years & 
Country) 
Procedure Clinical 
indication 
Radiotracer Scan range Characteristic of 
patient sample 
DRL dosimetry value E (mSv) 
A (MBq) 
[MBq/kg] 
CTDIvol and DLP 
(mGy) & 
(mGy.cm) 
A CT Total 
Watanabe et 
al21 
(JP, 2016) 
- 
 
- 
 
Myocardial/  
Metabolism 
Myocardial/ 
Metabolism 
Myocardial/  
Perfusion 
- 
 
- 
 
- 
 
- 
 
- 
15O-O2 g: 3D 
 
15O-CO g: 3D 
 
18F-FDG H 
 
18F-FDG D 
 
13N-NH3 
- 
 
- 
 
- 
 
- 
 
- 
- 
 
- 
 
- 
 
- 
 
- 
6600 
 
7125 
 
221 
 
251 
 
718 
- 
 
- 
 
- 
 
- 
 
- 
- 
 
- 
 
- 
 
- 
 
- 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Jallow et al23 
(US,2016) 
Oncology 
 
- 18F-FDG - 2010-14: 35, 65, 
76, 42 and 14 cases 
- 9.8, 9.8, 10.2, 9.7 
and 9.7 
- - - 
Willegaignon 
et al22 
(BR, 2015) 
Oncology/ 
inflammation 
 
Brain 
 
Bone 
Tumour/  
Inflammation 
 
- 
 
- 
18F-FDG 
 
18F-FDG 
 
18F-NaF 
- 
 
- 
 
- 
- 370 
 
350 
 
370 
6.76±1.08 
 
5.11±1.52 
 
7.30±0.30 
- 
 
- 
 
- 
- 
 
- 
 
- 
- 
 
- 
 
- 
Alessio et al19 
 
(USA, 2015) 
Whole body - 18F-FDG - 1-5 (4.3±1.3) cases  592 - - - - 
Oliveria et al26 
(BR, 2013) 
18F-FDG PET Cancer 18F-FDG - - 387.7 
[5-5.4] 
- - - - 
Roch et al25 
(FR, 2013) 
18F-FDG PET - 18F-FDG - 20 (60-80 kg) 350 and 337 
[5] 
- - - - 
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Table 2. Summary of hybrid PET/CT DRL methods (continued). 667 
Authors 
(Years & 
Country) 
Procedure] Clinical 
indication 
Radiotracer Scan range Characteristic of 
patient sample 
DRL dosimetry value E (mSv) 
A(MBq) 
[MBq/kg] 
CTDIvol and DLP 
(mGy) & 
(mGy.cm) 
A CT Total 
Botros et al28 
(AU & NZ, 
2009) 
Whole body 
 
Brain 
 
Myocardial 
Viability 
Tumour 
 
- 
 
- 
18F-FDG 
 
18F-FDG 
 
18F-FDG 
- 
 
- 
20 per exam or 
facility guidance 
level for 70-80 kg 
385 
 
385 
 
370 
- 
 
- 
 
- 
- 
 
- 
 
- 
- 
 
- 
 
- 
- 
 
- 
 
 
Hart et al29 
(UK, 2005) 
Tumours PET Tumour 18F-FDG - - 400 - 7 - - 
Brix et al30 
(DE, 2002) 
Oncology 
 
Neurology 
 
Cardiology 
 
Other  
application 
- 
 
- 
 
- 
 
- 
18F-FDG - - 370 (2D) 
 
200 (3D) 
- 
 
- 
7 
 
3.8 
- 
 
- 
- 
 
- 
 668 
Note: TOF= Time of flight,  15O-CO2= 15 Oxygen Carbon dioxide, 
15O-CO 15=  Oxygen Carbon monoxide, HP= hospital product,, g= gas,  
13N-NH3= N13 ammonia, NaF= Sodium Fluoride,, A.A 669 
=administered activity. 670 
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 680 
 681 
Table 3. Summary of hybrid SPECT/CT DRL methods. 682 
Authors 
(Years & 
Country) 
Procedure Clinical 
Indication 
Radiotracer Characteristi
c of patient 
sample 
DRL dosimetry value E (mSv) 
A (MBq) 
[MBq/kg] 
CTDIvol and DLP 
(mGy) & 
(mGy.cm) 
A CT Total 
Iball et al18 
(UK, 2017) 
Bone 
 
Parathyroid 
 
Post-thyroid 
ablation 
Tumour MIBG 
 
Octreotide 
 
 Myocardial 
Bone* 
 
Adenoma 
 
Post-thyroid  
Ablation* 
Tumour MIBG* 
 
Octreotide* 
 
Myocardial* 
 
99mTc-phosphates 
99mTc-sestamibi 
131I-iodide 
123I-MIBG 
111In-octreotide 
99mTc-sestamibi 
30 per each 
exam 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
4.9 and 150 
 
5.6 and 170 
 
5.9 and 210 
 
5.5 and 240 
 
5.5 and 240 
 
2.1 and 3.6 
3.9 
 
8.1 
 
- 
 
5.2 
 
11.9 
 
7.2* and 6.3 
- 
 
1.4 
 
1.5 
 
- 
 
3.3 
 
0.9* 
- 
 
9.5 
 
- 
 
- 
 
15.2 
 
8.1 
Avramova-
Cholakova et 
al24 
(BG, 2015) 
Breast 
 
 
Bone 
 
 
Thyroid 
 
Parathyroid 
 
 
Thyroid 
 
 
Lymphatic 
 
Lung perfusion 
- 
 
 
- 
 
 
- 
 
- 
 
 
Metastasis 
 
 
- 
 
- 
99mTc-sestamibi and 
tetrofosmin 
 
99mTc-MDP 
 
 
99mTc-pertechnetate 
 
99mTc-sestamibi 
 
 
131I-iodide 
 
 
99mTc-Nanocoll 
 
99mTc-MAA 
H1,2, and 3:64, 
9 , and 18 
 
H1,3, and 4:42, 
35, and 13 
 
H1:14 
 
H1,2, and 3:7, 
10, and 10 
 
H1,1  and 2: 
12,7, and 10 
 
H1 and 2:10 
and 20 
 
H2,3, and 4 : 20, 
14, and 19 
700 
 
 
600 
 
 
74 
 
120 
 
 
185 
 
 
74 
 
20 
3 and 100 
 
 
3 and 200 
 
 
4 and 170 
 
2.6 and 100 
 
 
4 and 170 
 
 
4 and 120 
 
2.6 and 100 
6.3, 5.9, and 
2.8 
 
2.5, 3.4, and 2.9 
 
 
1 
 
7.4, 6, and 5 
 
 
167, 167, and 74 
 
 
0.3 and  0.2 
 
1.1, 2, and 2 
 
3.2, 1.7, and 
1.5 
 
1.2, 1.8, and 
7.2 
 
3.6 
 
4.1, 2.3, and 
1 
 
1, 0.5, and 
2.4 
 
2.8 and 2.1 
 
1.4, 1.3, and 
8.5 
 
9.5, 7.6, and 4.3 
 
 
3.8, 5.1, and 10.1 
 
 
4.6 
 
11.5, 8.3, and 2 
 
 
- 
 
 
3.1 and 2.2 
 
2.5, 3.3, and 10.5 
 
: 683 
Table 3. Summary of hybrid SPECT/CT DRL methods (continued). 684 
Authors 
(Years & 
Country) 
Procedure Clinical  
indication 
Radiotracer Characteristic of 
patient sample 
DRL dosimetry value E (mSv) 
A (MBq) 
[MBq/kg] 
CTDIvol and DLP 
(mGy) & (mGy.cm) 
A CT Total 
Willegaignon 
et al22 
(BR, 2015) 
Brain/ 
Perfusion 
Brain/ 
Tumour 
- 
 
Tumour 
99mTc-ECD 
201Tl-chloride 
- 
- 
1203 
 
185 
- 
 
- 
8.17±1.69 
 
43.40±47.8 
- 
 
- 
- 
 
- 
Alessio et al19 
 
(USA, 2015) 
Bone  99mTc-MDP 1-4 (2.2±0.8) 
cases 
999 - - - - 
Heart et al29 
(UK, 2005) 
Bone 
 
Lung  
Perfusion 
Myocardial 
 
Myocardial 
 
Myocardial 
 
CBF 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
99mTc-MDP 
99mTc-MAA 
99mTc- tetrofosmin 
99mTc-sestamibi 
201Tl-chloride 
99mTc-Exam 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
800 
 
100 
 
400 
 
400 
 
80 
 
500 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
3 
 
0.3 
 
3.1 
 
3.7 
 
12.9 
 
4.8 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 685 
Note MIBG= metaiodobenzylguanidine, *= stress, H= hospital, MAA= macro aggregated albumin, ECD= ethyl cysteinate dimer, EXAM= Exametazime, Bone*= metastatic disease, equivocal uptake on 686 
planar studies, characterisation of lytic and sclerotic lesions, localise and characterise site of unexplained pain, localise and characterise site of multifocal pathology, evaluation of new/persistent symptoms 687 
following orthopaedic intervention, Post-thyroid ablation*= identify remnant thyroid tissues, and undertake accurate staging, Tumour MIBG*= Neuroendocrine tumour imaging, assessment of disease, 688 
suitability for therapy and response,  identification of primary tumours and metastases, assessment of post-therapeutic tumour targeting, and assessment of tumour recurrence, Octreotide*= Somatostatin 689 
receptor imaging – assessment of disease, suitability for therapy and response, identification of primary tumours and metastases, assessment of post-therapeutic tumour targeting, and assessment of tumour 690 
recurrence, Myocardial*= myocardial perfusion imaging and/or viability, and qualitative assessment of coronary calcium, CBF= cerebral blood flow. 691 
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 696 
 697 
 698 
Table 4. Summary of hybrid NM/CT equipment. 699 
Authors  
(Years &country) 
Modality Number Manufacture Year of installation Type of detectors 
Non-TOF TOF 
Kwon et al15 
(KR, 2016) 
PET/CT 105 GE discovery (45): Discovery 600 (5), 690 (8), 
710 (7), ST (4), STE (12), STE8(1), STE16(6), 
VCT(2) 
Philips (18): GXK6 (1), 16POWER (1), TF (4), 
TF16 (4), TF64 (8). 
Siemens (41): DUO (2), True Point (1), True 
point2 (2), True point6 (4), True point16 (2), 
True point 40 (12), True point64 (1), mCT20 
(2), mCT40 (1), mCT 64 (5), mCT 128 (6), 
mCT X4R (1), mCT FLOW (2)  
No data (1) 
2000-5 
 
2006-10 
 
2011-15 
 
- 
BGO (30) 
GSO (3) 
LBS (15) 
LSO (42) 
LYSO (14) 
- 
- 
- 
Jallow et al23 
(US,2016) 
PET/CT 158 GE (81) 
Philips (20) 
Siemens (56) 
Toshiba (1) 
2001-2013 
2004-2013 
2003-2002 
2005 
- 
- 
- 
- 
LYSO (158) 
- 
- 
- 
Avramova-
Cholakova et al24 
(BU, 2015) 
SPECT/CT 4 GE (1): Discovery NM/CT 670 with 16- 
detector row CT. 
Siemens (3): Symbia 2T (2) with a 2 detector 
CT row,  Symbia T16 (1) with a 16 detector row 
CT  
- 
- 
- 
- 
- 
- 
- 
- 
Willegaignon et al22 
(BR, 2015) 
PET/CT 
 
SPECT/CT 
- 
 
- 
GE (48%) 
Elscint (20%) 
Siemens (17%) 
Philips (12%) 
Other (3%) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Oliveira et al26 
(BR, 2013) 
PET/CT 42 GE (11) 
Philips( 8) 
Siemens (20) 
- 
- 
- 
BGO (3) 
GSO (3) 
LSO (18) 
Nal (Ti) (2) 
LYSO (2) 
- 
- 
- 
 700 
Table 4. Summary of hybrid NM/CT equipment. 701 
Authors  
(Years &country) 
Modality Number Manufacture Year of installation Type of detectors 
Non-TOF TOF 
Hart et al29  
 (UK, 2005) 
PET/CT 
 
SPECT/CT 
7% (PET) 
 
75% (SPECT) 
 
GE  (4)   
Siemens  (3) 
GE (45%)  
Siemens (23%) 
Philips (25%) 
Park (0.8%) 
Toshiba (6%) 
 Mediso (0.4%) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Brix et al30 
 (DE, 2002) 
PET/CT - 2 D and 3D PET equipment - 
- 
- 
- 
- 
- 
 702 
Note: GE= General electric, BGO= Bismuth germinate oxide, GSO= Gadolinium oxyorthosilicate, LBS= Lutetium based scintillators,  LSO= Lutetium oxyorthosilicate, LYSO= Lutetium yttrium oxyorthosilicate,  Nal 703 
(TI)=  Sodium iodide doped with thallium, and Min= Minutes. 704 
 705 
Figure 1. Flow diagram of included and excluded PET/CT and SPECT/CT NDRL studies. 706 
  707 
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1055 articles identified 
through the literature 
search. 
 
644 articles after removing duplicates 
33 articles assessed for full-text 
review 
611 articles excluded based on screening of 
titles or abstracts using general criteria for 
establishing DRLs in PET/CT and SPECT/CT 
examinations 
19 articles excluded after full-
text review: 
 
 Did not report NDRLs 
for PET/CT and 
SPECT/CT 
 Reporting local DRL 
 
 
14 articles included 
Two articles identified 
through other resources 
 
 708 
